Physician profile
Danielle Ryan
NPI 1467070490
$2,505.89
in general payments reported to CMS, 2019-2025
21 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.15 · 2022: $668 · 2023: $612 · 2024: $735 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.39 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $321.23 | 2022-2025 | Airsupra |
| Abbvie INC. | $200.79 | 2022-2025 | |
| Amgen INC. | $173.61 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $151.50 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Grifols USA, LLC | $149.79 | 2022-2023 | Prolastin-C Liquid |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Dexcom, INC. | $125.00 | 2022 | |
| Exact Sciences Corporation | $118.83 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $103.40 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $93.81 | 2023-2024 | Veozah |
| Lilly USA, LLC | $93.20 | 2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $85.40 | 2024 | Auvelity |
| Sanofi-Aventis U.S. LLC | $84.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.93 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $59.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.15 | 2024 | |
| Corcept Therapeutics | $20.85 | 2023 | Korlym |
| Seqirus USA INC | $18.76 | 2025 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $15.30 | 2024 | Inspire |
| Pfizer INC. | $13.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.